You are here

P&T News

November 21

Tablet is difficult to crush, break, or dissolve for illicit use
GAPVAC trial matches vaccines to individual glioblastoma patients
Surgical membrane heals damage with vitamin A derivative
No approved vaccines are available for this indication
‘The crisis is worsening,’ editorial writers say

November 20

Price of Sovaldi caught payers by surprise, expert says
Seventy percent response rate observed in ongoing phase II study
Oncologists expected to embrace lower-cost alternatives to Neupogen

November 19

FDA submission expected later this year

November 18

Researchers investigate famciclovir/celecoxib combo
NIH studies find limited kidney benefit from more rigorous blood pressure treatment
Equipment could be ‘game-changer’ in glioblastoma treatment

November 17

Second virus-related death in U.S.
Treatment improves progression-free survival compared with chemotherapy alone
Presence of type-1 interferon helps guide treatment choices
More than 80% of patients show no progression of joint structural damage
Approval based on data from two pivotal studies

November 14

Results are obtained within 90 minutes
New testing sought for Mallinckrodt and Kudco Ireland ADHD drugs
Two-day meeting of experts seeks to prioritize global efforts
Improper contact lens habits pose major risk for serious infections
Approval decision expected early next year with ‘priority review’

November 13

No FDA-approved meds can counteract antiplatelet effect
Analysis combines questionnaire, genetic profiling, and mammography scans
Experts clarify areas of agreement across multiple guidelines
TNF-alpha inhibitors face competition from biosimilars

November 12

Health care executives see $1 million in added supply-chain costs
Procalcitonin levels differentiate bacterial and viral infections
Health workers can grab quick refresher course
Treatment meets all primary and secondary endpoints

November 11

Findings add to debate over early cancer-detection methods
Perceived financial burden can lead to non-adherence
Most overdoses involved prescription drugs, authors find
New data raise questions about traditional management after hospital discharge

November 10

Nearly 5 million people treated each year
Daclatasvir, asunaprevir, and beclabuvir achieve 93% ‘cure’ rate
Reviewers question risk–benefit profile
Promotional claims omit risk information



From Sovaldi to Ebola: A Wide-ranging Interview with Dr. David Nash

A leading authority on population health, Dr. David Nash is optimistic about the future of disruptive innovation to improve healthcare in the U.S. The interview was conducted by P&T Editor Sonja Sherritze.


Free App

MediMedia App IconManaged Care, and P&T are available for free on multiple mobile platforms and devices. For Apple and iOS devices, visit the Apple Store and download the free digital application for Managed Care and P&T. Search for "Managed Care," "Pharmacy and Therapeutics," or "MediMedia."

Users of Android, Blackberry, Nook, and Kindle can view the mobile version on their respective devices by visiting these Web sites: Managed Care and P&T.